Instituto Rosenbusch (BUE:ROSE) Owner Earnings per Share (TTM): -23.26 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
22 GF Score
Price ARS154.00
GF Value ARS65.64
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Owner Earnings per Share (TTM)?

Instituto Rosenbusch BUE:ROSE 22 Owner Earnings per Share (TTM) is -23.26 as of Mar. 2026. GuruFocus rates BUE:ROSE with a GF Score™ of 22/100 and a GF Value™ of ARS65.64 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 463 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 215982.51% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Instituto Rosenbusch's Owner Earnings per Share (TTM) ended in Mar. 2026 was ARS-23.26. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Instituto Rosenbusch's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Instituto Rosenbusch was 78.57. The lowest was 2.24. And the median was 9.86.


BUE:ROSE's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.77
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Instituto Rosenbusch's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was ARS-11.36. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-100.15. It's PE Ratio (TTM) ratio for today is At Loss.

Instituto Rosenbusch's EPS without NRI for the three months ended in Mar. 2026 was ARS-9.83. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-98.62. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Instituto Rosenbusch Owner Earnings per Share (TTM) Related Terms


Instituto Rosenbusch Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Owner Earnings per Share (TTM) Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.42 1.24 -11.39 -4.67 7.35

Instituto Rosenbusch Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.64 -35.39 -39.89 7.35 -23.26

BUE:ROSE vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instituto Rosenbusch Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Price-to-Owner-Earnings falls into.


BUE:ROSE
22GF Score
Instituto Rosenbusch SA BUE:ROSE
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Instituto Rosenbusch Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Instituto Rosenbusch's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -4,265
Depreciation, Depletion and Amortization 110
Change In Deferred Tax 48
5Y Average of Maintenance Capital Expenditure 48
Change In Working Capital 3,164
Shares Outstanding (Diluted Average) 43

1. Start with "Net Income" from income statement. Instituto Rosenbusch's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was ARS-4,265 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Instituto Rosenbusch's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was ARS110 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Instituto Rosenbusch's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was ARS48 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = ARS48 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Instituto Rosenbusch's 5-Year Average Maintenance Capital Expenditure = ARS48 Mil

5. "Change In Working Capital" is from cashflow statement. Instituto Rosenbusch's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was ARS3,164 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Instituto Rosenbusch's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 42.589 Mil.

Instituto Rosenbusch's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -4265.301 +110.343+48.051
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-47.810315789474+3164.246)/42.589
=-23.26

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=154.00/-23.26
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -23.26 mean?
Instituto Rosenbusch (BUE:ROSE) has a Owner Earnings per Share (TTM) of -23.26 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Instituto Rosenbusch. According to the industry distribution chart, Instituto Rosenbusch ranks #999999 out of 463 companies in the Drug Manufacturers industry.
Is Instituto Rosenbusch's Owner Earnings per Share (TTM) too high?
Instituto Rosenbusch's current Owner Earnings per Share (TTM) is -23.26. Based on the distribution chart, Instituto Rosenbusch ranks #999999 out of 463 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #999999 out of 463 companies for Owner Earnings per Share (TTM). This places Instituto Rosenbusch in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 22.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 22.77, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Instituto Rosenbusch. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Owner Earnings per Share (TTM) is -23.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS65.64, compared to a current price of ARS154.00 — trading 134.6% above its estimated fair value. The current Owner Earnings per Share (TTM) is -23.26. Instituto Rosenbusch's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Owner Earnings per Share (TTM) is -23.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS154.00 is trading 134.6% above its estimated GF Value™ of ARS65.64. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Owner Earnings per Share (TTM): -23.26
  • GF Value™: ARS65.64 vs. price of ARS154.00 (134.6% above fair value)
  • GF Score™: 22/100 with 5 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
22GF Score

Get the complete analysis for BUE:ROSE

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS154.00
Price
ARS65.64
GF Value